Tumor cell surface proteoglycan and glycan

Tumor cell surface proteoglycans and glycans are not singular molecules but encompass a diverse group of complex macromolecules present on the surface of tumor cells. **Proteoglycans** are composed of a core protein covalently attached to glycosaminoglycan (GAG) chains and play central roles in cell signaling, mechanotransduction, and extracellular matrix organization. **Glycans**—the carbohydrate moieties of glycoproteins and glycolipids—modulate cell–cell and cell–ECM interactions, regulate cell proliferation, migration, immune responses, and influence metastatic behavior[1][2][3][4][5][6]. In cancer, altered expression and glycosylation patterns of these molecules lead to increased matrix stiffness, support malignant transformation, promote invasion and metastasis, modulate immune escape mechanisms, and contribute to resistance to therapy. While glycan and proteoglycan-targeting strategies are under investigation (e.g., chemical inhibitors of glycosylation, AGE-breakers), the non-specific and ubiquitous nature of these molecules presents significant therapeutic and safety challenges. **Correction/limitation:** This "target" does not represent a single, well-defined protein, receptor, or enzyme, but rather a heterogeneous class of molecules with diverse structures and functions. Targeting "tumor cell surface proteoglycans and glycans" is conceptually valid for research and therapy but does not correspond to a specific drug target (such as a receptor or an enzyme); instead, it refers to a broad family of surface molecules frequently altered in cancer. **Summary of why is_incorrect is true:** - The entry is too broad/generic to be mapped to a unique canonical target - It refers to a molecular class rather than a discrete therapeutic target - No universal abbreviation or specific drug-gene interaction exists for the full set of proteoglycans and glycans - Examples (such as syndecan-1, glypican-3, or CD44) would be required for more structured information on specific, actionable targets

Other names

Proteoglycan, glycan (general terms)cell-surface proteoglycancell-surface glycantumor glycocalyx

Inhibition/modulation of glycosylation (e.g., alters glycan structure/content)[2] Disruption of glycan-mediated ECM stiffening (e.g., AGE-breakers)[2] Blockade of proteoglycan growth factor co-receptor activity Cell signaling pathway inhibition